Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The CHAPERONE Study: Microdosed Atropine for Pediatric Myopia
NCT03942419Phase 3Terminated
- Sponsor
- Hyperion DeFi
- Start
- Jun 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NVK002 in myopia (3 arms), sponsored by Hyperion DeFi. Primary endpoint: Myopia progression at 36 months. Started Jun 2019; status: terminated.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT03942419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942419.